Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency

Angiology

Volumn 52, Issue 8 SUPPL. 1, 2001, Pages

  Ramelet, A A ^a  

^a NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DAFLON; DIOSMIN; FLAVONOID; HESPERIDIN; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; PLACEBO; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; CAPILLARY PERMEABILITY; CHRONIC VEIN INSUFFICIENCY; CLINICAL TRIAL; DERMATITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LEG ULCER; REVIEW; SCLERODERMA; SKIN EDEMA; TREATMENT INDICATION; TREATMENT OUTCOME; ARTICLE; CLINICAL TRIAL (TOPIC); DOUBLE BLIND PROCEDURE; LEG EDEMA; LEG VARICOSIS; MICROCIRCULATION; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PHARMACOLOGICAL PARAMETERS; PREVALENCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SCLEROTHERAPY; SKIN DISEASE; VEIN TONE; VENOUS REFLUX;

EID: 0034883342     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319701052001s07     Document Type: Review

References (44)

1. Prospektive epidemiologische studie über die entstehungsweise der krampfadern bei kindern und jungendlichen (Bochumer Studie I und II)
2. Etude épidémiologique sur la pathogenèse des varices (études de Bochum I-III)
3. Varicose veins and chronic venous insufficiency in Brazil: Prevalence among 1,755 inhabitants of a country town
4. Venous thromboembolism and other venous disease in the Tecumseh community health study
5. The management of chronic venous disorders of the leg: An evidence-based report of an international task force
6. Varicose veins and chronic venous insufficiency - Prevalence and risk factors in 4,376 subjects in the Basle Study II
7. Reporting standards in venous disease: An update
8. Venous scoring: An adjunct to venous outcome assessment
9. Epidemiology of CVI
10. Leg ulcers: Epidemiology and aetiology
11. Prevalence of non-healed and healed chronic leg ulcers in an elderly rural population
12. Venenerkrankungen, ein kostintensives krankheitsgeschehen
13. Management of venous leg ulcer by French physicians, diversity and related costs: A prospective medicoeconomic observational study
14. Colour duplex ultrasonography in the rational management of chronic venous leg ulcers
15. Ulcère veineux, approche dermatochirurgicale et chirurgicale
16. Role of microangiopathy in the development of venous leg ulcers
17. Causes of venous ulceration: A new hypothesis
18. Neutrophil activation and mediators of inflammation in chronic venous insufficiency
19. The human saphenous vein in pharmacology: Effect of a new micronized flavonoid fraction (Daflon 500 mg) on norepinephrine-induced contraction
20. Mecanisme d'action Daflon 500 mg sur le tonus veineux noradrénergique
21. Etude de l'activité pharmacodynamique de Daflon 500 mg
22. Venous elasticity after treatment with Daflon 500 mg
23. Effects of Daflon 500 mg on increased microvascular permeability in normal hamsters
24. Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease - A prospective study
25. Effects of Daflon 500 mg on postischemic macromolecular leak syndrome in striated skin muscle of the hamster
26. Postischemic leukocyte/endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: Cellular mechanisms and effect of Daflon 500 mg
27. Inflammation in chronic venous insufficiency: Is the problem insurmountable?
28. Safety of use of Daflon 500 mg confirmed by acquired experience and new research
29. Clinical evaluation of a venotronic drug in man
30. Quantification of edema using the volumeter technique; therapeutic application of Daflon 500 mg in chronic venous insufficiency
31. First consolidated European data
32. 131 - Albumin and Tc99m red cells. Application to the pharmacodynamic activity of Daflon 500 mg
33. Activité thérapeutique de Daflon 500 mg sur les troubles trophiques de l'insuffisance veineuse
34. Insuffisance veineuse: 580 Gynécologues de ville confirment l'efficacité de Daflon 500 mg de la jambe lourde aux troubles trophiques
35. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: A pilot study
36. Plasma VGEF during oral therapy in patients with chronic venous disease with purified micronized fraction. A pilot study
37. Oral administration of purified micronized flavonoid fraction suppresses leukocyte adhesion in ischemia-reperfusion injury: In vivo observation in the hamster skin fold
38. Efficacy of Daflon 500 mg in venous ulcer healing: A double-blind, randomized, controlled versus placebo trial in 107 patients
39. The beneficial augmentative effects of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: An open multicenter, controlled, randomized study
40. Flavonoids: A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders